Biological medicines, such as monoclonal antibodies, have revolutionized the treatment landscape for various diseases, offering targeted therapies that empower patients to manage their conditions effectively. Despite their efficacy, biologics come with a hefty price tag, comprising a significant portion of drug spending in the US. Biosimilars, akin to generic versions of small molecule drugs, have the potential to drive down costs and enhance treatment accessibility. However, unlike generics, biosimilars have faced hurdles in gaining widespread acceptance, particularly in the US. Proposed regulatory revisions by the Food and Drug Administration (FDA) hold the promise of easing constraints and facilitating broader availability of these game-changing therapies. Yet, further adjustments are necessary to fully capitalize on the benefits of biosimilars and ensure optimal patient outcomes.
Read more from bmj.com